Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.11% is 84% below its 5-year average of -22.29%, near the low end of its 5-year range (-41.11%–-13.00%).
42.13% below its 12-month average of -28.92%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.95%.
RETURN ON ASSETS (ROA)
-41.11%
RETURN ON ASSETS (ROA) AVG TTM
-28.92%
RETURN ON ASSETS (ROA) AVG 3Y
-26.43%
RETURN ON ASSETS (ROA) AVG 5Y
-22.29%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.13%
CURRENT VS 3Y AVG
-55.51%
CURRENT VS 5Y AVG
-84.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-27.51%
vs the sector median at left
Edgewise Therapeutics, Inc.
Market Cap
$4.31B
Return on Assets (ROA)
-41.11%
TTM Avg
-28.92%
3Y Avg
-26.43%
5Y Avg
-22.29%
Market Cap
$4.31B
Return on Assets (ROA)
-9.97%
TTM Avg
-20.59%
3Y Avg
-24.65%
5Y Avg
-22.36%
Market Cap
$4.37B
Return on Assets (ROA)
-34.36%
TTM Avg
-56.86%
3Y Avg
-55.14%
5Y Avg
-55.14%
Market Cap
$4.48B
Return on Assets (ROA)
28.79%
TTM Avg
8.79%
3Y Avg
1.95%
5Y Avg
1.56%
Market Cap
$4.12B
Return on Assets (ROA)
7.14%
TTM Avg
-3.40%
3Y Avg
-2.46%
5Y Avg
-5.09%
Market Cap
$4.11B
Return on Assets (ROA)
-29.57%
TTM Avg
-41.63%
3Y Avg
-37.55%
5Y Avg
-32.14%
Market Cap
$4.02B
Return on Assets (ROA)
-12.59%
TTM Avg
-11.38%
3Y Avg
-5.58%
5Y Avg
0.19%
Market Cap
$4.60B
Return on Assets (ROA)
4.59%
TTM Avg
-6.29%
3Y Avg
-18.57%
5Y Avg
-18.57%
Market Cap
$3.99B
Return on Assets (ROA)
0.76%
TTM Avg
-1.39%
3Y Avg
-1.28%
5Y Avg
0.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.31B | -41.11% | -28.92% | -26.43% | -22.29% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | -9.97% | -20.59% | -24.65% | -22.36% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | -34.36% | -56.86% | -55.14% | -55.14% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.48B | 28.79% | 8.79% | 1.95% | 1.56% |
| LivaNova PLC (LIVN)vs › | $4.12B | 7.14% | -3.40% | -2.46% | -5.09% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.11B | -29.57% | -41.63% | -37.55% | -32.14% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | -12.59% | -11.38% | -5.58% | 0.19% |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 4.59% | -6.29% | -18.57% | -18.57% |
| ICU Medical, Inc. (ICUI)vs › | $3.99B | 0.76% | -1.39% | -1.28% | 0.88% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 6.20% | 6.10% | 6.22% | 4.90% |
ROA
-41.1%
ROE
-44.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.36% |
| 2024-12-31 | -27.49% |
| 2023-12-31 | -29.46% |
| 2022-12-31 | -18.43% |
| 2021-12-31 | -15.01% |
| 2020-12-31 | -13.00% |
| 2019-12-31 | -38.65% |
